| Name | BAY-1816032 |
| Description | BAY-1816032 is a benzimidazole budding inhibition relieved homolog protein 1 kinase (BUB1) inhibitor with IC50 of 0.7 nM and is orally active and abolishes nocodazole-induced Thr-120 phosphorylation of histone H2A, a major BUB1 target protein, in HeLa cells with IC50 of 29 nM. |
| In vitro | METHODS: BAY-1816032 (0, 1.5625, 3.125, 6.25, 12.5, 25, 50 μM, 48 hours) treated ATC cells (TPC-1, 8505C), and CCK-8 assay was used to study cell viability.
RESULTS BAY-1816032 treatment resulted in a decrease in ATC cell viability, with IC50 values of 4.230 μM in TPC-1 cells and 6.216 μM in 8505C cells. [2]
METHODS: Colony formation assay, cell cycle, invasion, migration and wound healing assay were performed after ATC cells were treated with BAY-1816032 (0, 2.5, 5 μM).
RESULTS BAY-1816032 can significantly reduce colony formation ability; BAY-1816032 can cause cell cycle arrest similar to siRNA; BAY-1816032 treatment can significantly hinder the invasion and migration of ATC cells in a dose-dependent manner. [2] |
| In vivo | METHODS: BAY-1816032 (100 mg/kg, oral, 24 days) was used to treat 8505C xenograft model mice to evaluate the anti-ATC activity and safety of BAY-1816032 in mice.
RESULTS There was no significant difference in the body weight of each group of mice; the tumor weight of mice treated with BAY-1816032 was significantly reduced. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.74 mM), Sonication is recommended.
H2O : < 0.1 mg/mL (insoluble)
DMSO : 25 mg/mL (46.77 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | BUB1 kinase | BUB1 | BAY-1816032 | BAY1816032 | BAY 1816032 |
| Inhibitors Related | Culmerciclib | Fasudil | Bicyclol | Piceatannol | Chymotrypsin | Fasudil hydrochloride | Camostat mesylate | 6-(Dimethylamino)purine | FOY 251 | BMT-124110 Formate | Benzamidine hydrochloride | Cetraxate hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Post-Translational Modification Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
United States
